

ASX/Media Release

27/02/2020

## **Emerald Clinics to conduct opioid sparing clinical trial for Zelira (ASX:ZLD)**

### **Highlights**

- *Emerald Clinics to leverage its unique clinical and data platforms to accelerate trial*
- *Validates Emerald's capabilities to rapidly recruit and execute on high quality clinical trials*

**Emerald Clinics Limited (ASX: EMD)(Emerald or the Company)**, a company establishing and operating a network of clinics specialising in the creation of fit for purpose evidence to guide appropriate use of unregistered medicines, including cannabinoid treatments, is pleased to announce it has entered into a Clinic Trial Research Agreement to accelerate the completion of the Zelira sponsored trial named:

*"A study to evaluate the safety, tolerability, and pharmacokinetics of a medicinal cannabinoid oil formulation in chronic non-cancer pain participants on long term opioid treatments (Trial ID: ACTRN12619001013156)"*

Emerald Clinics Managing Director and CEO Dr Michael Winlo said:

*"We are pleased to be working with Zelira, who are investing in the rigorous, product specific clinical studies required to bring cannabinoid based medical products into the mainstream where appropriate. Undertaking this trial validates our model of co creating evidence with our patients while providing high quality care.*

*We are excited to be building upon the collaboration announced in 2019 and look forward to leveraging Real World Evidence (RWE) and traditional clinical trials to support Zelira's strategy and ultimately improve the health and wellbeing of our patients"*

Zelira's Managing Director, Dr Richard Hopkins, commented, *"We are delighted to have achieved full enrolment, which represents a major milestone for the trial. We're also pleased for the opportunity to expand our partnership with Emerald Clinics by bringing them on as a second site. We have been impressed by their ability to complement the efforts of the St Vincent team by rapidly screening and enrolling eligible patients into trial.*

*To our knowledge, this is the first clinical trial to be designed with a primary end-point assessing the efficacy of a full spectrum plant-derived cannabis formulation containing THC and CBD to reduce opioid dependence in chronic non-cancer patients. If successful, the outcome of these trials will likely have immediate impact in major global markets where opioid overuse and addiction is a major problem."*

The Clinic Trial Research Agreement formalises the arrangements of the binding letter of intent disclosed in the Company's Prospectus, dated 11 December 2019 that is available at:  
[www.emeraldclinics.com.au/investors/asx-announcements](http://www.emeraldclinics.com.au/investors/asx-announcements).

Release authorised by:

Dr Michael Winlo, CEO and Managing Director

### **For further information:**

Dr Michael Winlo  
CEO  
(08) 6559 2800  
[investors@emeraldclinics.com.au](mailto:investors@emeraldclinics.com.au)

Matt Wright  
Media/investor relations  
+61 (0) 451 896 420  
[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

**About Emerald Clinics Limited**

Emerald Clinics Limited (ACN 625 085 734) is an Australian incorporated company that operates a network of specialist medical clinics (Clinics) and uses purpose-built software and technology to gather high quality clinical data from informed and consenting patients to create robust and ethically-sourced evidence.

Emerald is a clinical services and healthcare technology company focussed on the provision of care for patients clinically determined to have exhausted conventional therapies and who may be suitable for cannabinoid-based medicines. In addition, Emerald uses technology to capture clinical data that can be used to generate clinical evidence relating to the safety and efficacy of unregistered medicines. Emerald has established four medical centres in Australia in Perth, Sydney, Melbourne and Northern Rivers NSW.

**Cautionary Note on Forward-Looking Statements**

Any statements in this press release about future expectations, plans and prospects for the Company, the company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a results of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.